Jiangsu Nhwa Pharmaceutical Co., LTD (SHE:002262)
China · Delayed Price · Currency is CNY 22.44
+0.22 (0.99%)
Apr 28, 2026, 3:04 PM CST
SHE:002262 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Net Income | 1,074 | 1,057 | 1,144 | 1,037 | 900.71 | 797.78 |
Depreciation & Amortization | 196.99 | 196.99 | 182.01 | 164.08 | 148.66 | 135.06 |
Other Amortization | 69.69 | 69.69 | 52.19 | 11.01 | 5.09 | 2.78 |
Loss (Gain) From Sale of Assets | -0.17 | -0.17 | -0.29 | -0.15 | -0.37 | 0.24 |
Asset Writedown & Restructuring Costs | 0.84 | 0.84 | -0.07 | -0.22 | 0.28 | 0.74 |
Loss (Gain) From Sale of Investments | -61.16 | -61.16 | -65.57 | -51.04 | -36.27 | -36.23 |
Provision & Write-off of Bad Debts | 9.02 | 9.02 | 33.95 | 15.16 | 1.1 | 6.99 |
Other Operating Activities | -146.45 | 31.71 | 40.78 | 34.29 | 2.09 | 42.38 |
Change in Accounts Receivable | -219.4 | -219.4 | -512.98 | -199.06 | -155.28 | -122.88 |
Change in Inventory | -125.89 | -125.89 | -71.8 | 54.43 | -128.19 | -205.88 |
Change in Accounts Payable | 135.42 | 135.42 | 81.71 | -33.91 | 126.92 | 77.1 |
Change in Other Net Operating Assets | 2.63 | 2.63 | 31.05 | -0.01 | - | 2.49 |
Operating Cash Flow | 916.95 | 1,078 | 916.13 | 1,008 | 861.02 | 701.12 |
Operating Cash Flow Growth | -8.47% | 17.71% | -9.14% | 17.11% | 22.81% | -43.84% |
Capital Expenditures | -444.67 | -437.41 | -450.06 | -373.99 | -327.75 | -206.11 |
Sale of Property, Plant & Equipment | 0.33 | 0.34 | 0.8 | 1.48 | 0.09 | 0.34 |
Cash Acquisitions | -0.08 | -0.08 | -0.34 | -0.13 | - | - |
Divestitures | - | - | - | - | - | 0.15 |
Investment in Securities | -171.12 | -171.16 | -1,008 | 37 | -393.6 | -221.4 |
Other Investing Activities | -557.52 | 46.37 | 46.12 | 42.25 | 32.36 | 34.49 |
Investing Cash Flow | -1,173 | -561.94 | -1,411 | -293.39 | -688.9 | -392.52 |
Long-Term Debt Issued | - | 30 | 65 | 80 | 40 | 38 |
Total Debt Issued | 91 | 30 | 65 | 80 | 40 | 38 |
Long-Term Debt Repaid | - | -45.54 | -141.05 | -87.55 | -78.04 | -62.67 |
Total Debt Repaid | -70.54 | -45.54 | -141.05 | -87.55 | -78.04 | -62.67 |
Net Debt Issued (Repaid) | 20.46 | -15.54 | -76.05 | -7.55 | -38.04 | -24.67 |
Issuance of Common Stock | - | - | 98.86 | - | - | - |
Repurchase of Common Stock | -4.35 | -4.35 | - | - | - | -0.46 |
Common Dividends Paid | -365.67 | -366.21 | -323.77 | -202.62 | -202.74 | -100.76 |
Other Financing Activities | -1.27 | - | - | - | - | -1.54 |
Financing Cash Flow | -350.83 | -386.1 | -300.97 | -210.17 | -240.78 | -127.43 |
Foreign Exchange Rate Adjustments | -0.23 | -1.04 | 0.17 | 0.41 | 0.91 | -1.14 |
Net Cash Flow | -607.16 | 129.32 | -796.15 | 505.15 | -67.75 | 180.02 |
Free Cash Flow | 472.28 | 640.98 | 466.07 | 634.31 | 533.27 | 495.01 |
Free Cash Flow Growth | -13.05% | 37.53% | -26.52% | 18.95% | 7.73% | -49.48% |
Free Cash Flow Margin | 7.86% | 10.84% | 8.18% | 12.58% | 12.41% | 12.58% |
Free Cash Flow Per Share | 0.47 | 0.64 | 0.46 | 0.63 | 0.53 | 0.49 |
Cash Interest Paid | - | - | - | - | - | 5.06 |
Cash Income Tax Paid | 772.26 | 749.73 | 738.14 | 677.61 | 543.1 | 545.21 |
Levered Free Cash Flow | 260.34 | 354.17 | 352.12 | 367.44 | 221.79 | 245.59 |
Unlevered Free Cash Flow | 261.71 | 355.69 | 354.64 | 370.04 | 224.88 | 248.76 |
Change in Working Capital | -225.86 | -225.86 | -470.43 | -201.76 | -160.26 | -248.62 |
Updated Mar 31, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.